Floatz logo

DACLIZUMAB

Leukemia

University of Maryland, Baltimoremonoclonal_antibodyPhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB

View all 50 →

Same molecule, other indications

DACLIZUMAB is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →
HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)Dormant
BB
Indicative ·
68 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →